Symptomatic Therapy for Patients With Huntington's Disease

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Treatments: Haloperidol; Haloperidol decanoate; Idebenone; Risperidone; Sertraline; Tetrabenazine; Ubiquinone

Criteria

Inclusion Criteria:

1. Genetic diagnosis of Huntington's disease

2. Symptomatic patients with Huntington's disease

3. Disease duration less than 5 years -

Exclusion Criteria:

(1) Movement disorder due to other definite causes instead of Huntington's disease (2) Severe Lung, kidney or liver disease (3) Neoplastic Disease

-